Research brief · Metabolic
Retatrutide
Triple incretin/glucagon receptor agonist for advanced metabolic and energy-balance research.
Class
Triple GIP/GLP-1/Glucagon agonist
Half-life
~6 days
Studied in
Adipose biology, mitochondrial activity, energy balance.
What it is
Retatrutide is an investigational triple agonist of GIP, GLP-1 and glucagon receptors. Glucagon receptor co-activation is hypothesized to amplify hepatic lipid oxidation and energy expenditure in research models beyond what dual incretin agonists achieve.
Mechanism studied
Simultaneous activation of three incretin/glucagon receptors.
Research notes
- Glucagon arm contributes to hepatic lipid oxidation endpoints in published preclinical work.
- Often examined alongside tirzepatide and semaglutide in comparative receptor pharmacology studies.
Before sourcing any material
- Confirm a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity).
- Check the stated peptide content per vial, not just the gross vial mass.
- Plan reconstitution volumes first so the vial size matches your protocol.
- Verify what is lawful in your jurisdiction — these are in-vitro research reagents, not medicines.